Carboplatin and Paclitaxel in Treating Older Patients With Metastatic or Recurrent Unresectable Non-small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin and paclitaxel in treating patients who have metastatic or recurrent unresectable non-small cell lung cancer.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/12/2016
Locations: CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio
Conditions: Lung Cancer
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if combination chemotherapy is more effective with or without radiation therapy for stage IIIA non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without radiat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2016
Locations: CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio
Conditions: Lung Cancer
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and paclitaxel in treating patients who have advanced or recurrent cancer of the urinary tract.
Gender:
ALL
Ages:
120 years and below
Trial Updated:
07/08/2016
Locations: McDowell Cancer Center at Akron General Medical Center, Akron, Ohio +3 locations
Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Completed
This is a non-randomized Phase II study. Patients determined at initial diagnosis to have a carcinoma of unknown primary site (CUP) will have their treatment selected with the use of a molecular profiling assay. The assay will be performed on paraffin-embedded tumor tissue from a biopsy specimen. Patients given specific diagnoses (e.g., lung, pancreas, colon, breast, renal cell, prostate and ovarian cancer) will receive treatment regimens of proven activity. If no specific diagnosis is made with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2016
Locations: Oncology Hematology Care, Cincinnati, Ohio
Conditions: Carcinoma
Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
Terminated
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, cisplatin, paclitaxel, and vinblastine, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide and cisplatin are more effective when combined with paclitaxel or vinblastine in treating germ cell tumors. PURPOSE: This randomized phase III trial is studying paclitaxel, ifosfamide, and cisplatin to see how well they work compared to vinblastine, ifosfamide, and cisplatin... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
07/01/2016
Locations: Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio
Conditions: Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin or leuprolide may stop the adrenal glands from producing androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, hormone therapy, and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying giving chemotherapy together w... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/01/2016
Locations: Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio
Conditions: Prostate Cancer
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
Unknown
The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide) followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with HER2-positive breast cancer. Trastuzumab will also be given to all patients after surgery. The study will also evaluate the toxi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/03/2016
Locations: Akron City Hospital, Akron, Ohio +5 locations
Conditions: Invasive Breast Cancer
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Completed
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2016
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio
Conditions: Non Small Cell Lung Cancer
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Completed
To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/11/2016
Locations: ProMedica Health System, Inc., Toledo, Ohio
Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Completed
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with paclitaxel and carboplatin is effective and safe in the treatment of squamous cell carinoma of the lung.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2016
Locations: Signal Point Clinical Research Center, LLC, Middletown, Ohio
Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients with metastatic melanoma of the eye that cannot be removed by surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2016
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Intraocular Melanoma
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
Completed
The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2015
Locations: Case Western Reserve Univ., Cleveland, Ohio
Conditions: Locally Recurrent or Metastatic Breast Cancer